# Mebendazole as Adjuvant Treatment for Colon Cancer

> **NCT03925662** · PHASE3 · RECRUITING · sponsor: **Sherief Abd-Elsalam** · enrollment: 40 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Folfox with avastin
- **DRUG:** Mebendazole

## Key facts

- **NCT ID:** NCT03925662
- **Lead sponsor:** Sherief Abd-Elsalam
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-01
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03925662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03925662, "Mebendazole as Adjuvant Treatment for Colon Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT03925662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*